Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04561869
Other study ID # PIC in Myopia
Secondary ID
Status Active, not recruiting
First received
Last updated
Start date October 15, 2020
Est. completion date November 15, 2021

Study information

Verified date September 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aim of the work PIC in pathological myopia has not been well documented due to difficult in diagnosis we conducted this retrospective study to characterize the clinical features of PIC in high myopic eye. - To show the diagnostic criteria of PIC lesions in high myopic patients. - Find out the prevalence of PIC related 'patchy atrophy' - To determine risk factor for developed PIC in a series of highly myopic patients. - Role of PIC in progression of high myopia. - Calculate the progression rate of PIC related lesion, by the size change during follow-up. - Search about complication of PIC in myopia. Patient and Methods This retrospective observational case series study included patients with high myopia who had been examined and followed-up in the High Myopia Clinic of the Tokyo Medical and Dental University. Approval from Ethics Committee of Tokyo Medical and Dental University was obtained, adhering to the tenets of Declaration of Helsinki. Signed informed consent documentation was obtained from all participants. All study participants underwent a detailed ophthalmologic examination at baseline and at each follow-up visit. The examinations included measurements of best-corrected visual acuity (BCVA) using a Landolt C chart, refraction, slit lamp biomicroscopy, biometry for determination of axial length, (IOL Master; Carl Zeiss Meditec Co, Jena, Germany), fundus examination in medical mydriasis, fluorescein angiography, was performed with and colour fundus photography , and assessment of fundus autofluorescence (TRC-50DX; Topcon, Tokyo, Japan) a or the Heidelberg Spectralis HRA system. Swept source Optical coherence tomography (OCT) used in assessment of the RPE and photoreceptors using a (DRI-OCT;Topcon, Tokyo, Japan). As scanning protocols, 9 mm or 6 mm radial with 12 equal meridian scans were performed. The swept-source OCT device has an A-scan repetition rate of 100 000 Hz, and its light source operates in the wavelength range of 1 μm.


Myopia The frequency of myopia and high myopia are growing on a worldwide for causes that not cleared. Myopia is vision challenges due to rises the risk of pathologic ophthalmic changes such as cataract, glaucoma, retinal detachment, and myopic macular degeneration, all of which can cause permanent vision loss. High myopia was defined as an error of refractive above 8.0 diopters (D) or an axial length of 26.5 mm or more. Younger persons than 5 years, high myopia was defined by a refractive error of below- 4.0 D, and in children between 5 to 8 years, high myopia was defined by error of refraction below -6.0 D. The term of pathologic myopia," "high myopia," and "axial myopia" have been used as a same in the literature. Pathologic myopia was defined as chorioretinal atrophy (by META-PM study group classification) with/or the existence of posterior staphylomas. Pathologic myopia is an significant origin of vision loss global, affecting up to 3% of the people. The effect of myopic maculopathy on impairment of vision is critical because the maculopathy is often affect both eye , permanent, and usually affects individuals in productive years. Punctate inner choroidopathy Definition Punctate inner choroidopathy (PIC), classically bilateral and is considers one of "white dot syndromes" which usually presents with distinct ,multiple white-yellow lesions at posterior pole in the level of inner choroid and outer retina with a preference for young myopic female , without sign of old or recent anterior chamber or vitreous inflammation , with an increase the incidence of macular neovascularization (MNV). ETIOLOGY The underlying pathophysiology are not completely understood. Multiple evanescent white dot syndrome( MEWDS)-like findings have been presented after traumatic subretinal bleeding, choroidal rupture, and penetrating injury or with angioid streaks, ensuring antigen exposure is likely causative factor. The present of acute retinopathy in Pseudoxanthoma elasticum (PXE) is marked along angioid streaks (breaks in the Bruch membrane), in which contact of retinal, RPE, and the Bruch membrane antigens to the immune system which stimulate an autoimmune system. . Most inflammatory conditions in myopia are including the choriocapillaris. It can be suggested that weakness of the choriocapillaris due to anatomic changes in addition to unknown immunogenetic factors potentiate myopic eyes to primary inflammatory choriocapillaropathies. CLINICAL FINDINGS Symptom Vision was usually slightly affected until the lesions were subfoveal or choroidal neovascular membranes developed.(8) According to the study by Gerstenblith and colleagues, initial symptoms in PIC are mostly scotoma (91%), blurred vision (86%), photopsia (73%), floaters (69%), photophobia (69%), and metamorphopsia (65%). Loss of peripheral vision was reported in 26% of patients. The consequence variable from return to the normal to bilateral profound loss of vision . Sign Tools used in detecting and following PIC have involved fluorescein angiography, indocyanine green angiography, and OCT ,fundus autofluorescence (FAF) imaging and OCT angiography. Fundoscopic features Small (100-300 microns), yellow-gray lesions (12-25 in number) which usually limited to the posterior pole and scattered in a haphazard (or rarely, linear) form. The development of chorioretinal scars is frequency to occur as consequence at the sites of inflammation. Then, these scars become increasingly to well-defined ("punched out") and may come to be pigmented. These scars may progressively enlarge in size, leading to deterioration of symptoms over time. OCT finding: Stage I: minor irregularities change in the outer nuclear layer. Stage II: focal elevation of the retinal pigment epithelium/Bruch's membrane (RPE/BrM) complex with EZ and interdigitation zone disruption. Stage III: The lesion of moderate reflectivity breakdowns through the RPE and then grow to the dome of OPL through the photoreceptor layer. The RPE remain and BM at the break gradually disappear, exposing the choroidal part of the lesion. Stage IV: The lesion descends from the peak toward the choroidal part, subsequently a herniation of the OPL and inner retina (with a V-shaped change) through the defect in the RPE and BM. Stage V: The photoreceptor layer around the lesion is progressively missing with the drooping of the OPL and inner retina. This lead to V-shaped inward of the outer plexiform layer and inner retina into the choroid this is called "focal choroidal excavation .At the same time, RPE proliferation occurs (with posterior shadowing) to repair the RPE break so, the OPL framework reappear . BM (Bruch's membrane); OPL (outer plexiform layer;) RPE ( retinal pigment epithelium), SD-OCT( spectral-domain optical coherence tomography). fluorescein angiography (FA)& Indocyanine green angiography (ICG) FA in PIC patients show early hypofluorescence with late staining of inflammatory lesions, early hyperfluorescence can also happen, particularly if CNV is found. ICG shows midphase hypocyanescence at the posterior pole that may go beyond the lesions visible on FA and fundus. Fundus autofluorescence (FAF) Active PIC lesions show hypoautofluorescent spots with a hyperautofluorescent border that disappear as the lesions regress. Atrophic PIC lesions display to be hypoautofluorescent. Complication Serious visual loss occurs in about to 40% of patients mainly due to development of choroidal neovascularization (CNV). The Important associations of myopic choroidal neovascularization (MCNV) in highly myopic eyes with increasing levels of vascular endothelial growth factor or inflammatory cytokines and maculopathy lesions firmly indicate an association of inflammation in the cause of MCNVs. Management The PIC management is tricky for multiple reasons. The varying in seriousness of disease between patients make that ideal l treatment range from observation to immunosuppression or intravitreal anti-VEGF therapy. The judgment whether a patient is benefit from maintenance therapy is hard due to the need to sense of balance between the varying outcome of patients with PIC and the hazards of immunosuppression. Large number of patients with PIC have prolonged times without disease activity and may go into long-standing remission, although in others these stable stages may be interrupted by unpredictable, sight-threatening episodes. Also, the evidence base to recommend any treatment approach is inadequate There is large difference between patients. So, mediation is necessary to treat new or active inflammatory "PIC" lesions especially when threatening the fovea, and to handle secondary CNV. Also, addition, the situation of the other eye requires attention. The treatment options include local and systemic corticosteroids, systemic immunomodulatory drugs, intravitreal VEGF inhibitors (anti-VEGF), photodynamic therapy (PDT), argon laser, and submacular surgery.

Recruitment information / eligibility

Status Active, not recruiting
Enrollment 39
Est. completion date November 15, 2021
Est. primary completion date October 15, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Highly myopic patients. - Men and women aged over 18 years - Fundus changes typical of pathological myopia - Minimum follow up period of 2 years Exclusion Criteria: - Another choroidal lesion other than MFC. - Media opacity interfere with quality of image taking. - Alternative diagnosis (especially other white dot syndromes or when it was unclear whether the lesions were due to pathologic myopia) - If they had an underlying systemic condition that could mimic PIC (e.g., sarcoidosis, TB,) - If they had history of travel to Histoplasma-endemic regions

Study Design

Related Conditions & MeSH terms


Country Name City State
Japan Tokyo Medical and Dental University Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted


References & Publications (5)

Fang Y, Yokoi T, Nagaoka N, Shinohara K, Onishi Y, Ishida T, Yoshida T, Xu X, Jonas JB, Ohno-Matsui K. Progression of Myopic Maculopathy during 18-Year Follow-up. Ophthalmology. 2018 Jun;125(6):863-877. doi: 10.1016/j.ophtha.2017.12.005. Epub 2018 Jan 19. — View Citation

Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, Rahi J, Resnikoff S, Vitale S, Yannuzzi L. IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M20-M30. doi: 10.1167/iovs.18-25957. Review. — View Citation

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. Review. — View Citation

Niederer RL, Gilbert R, Lightman SL, Tomkins-Netzer O. Risk Factors for Developing Choroidal Neovascular Membrane and Visual Loss in Punctate Inner Choroidopathy. Ophthalmology. 2018 Feb;125(2):288-294. doi: 10.1016/j.ophtha.2017.09.002. Epub 2017 Oct 6. — View Citation

Zarranz-Ventura J, Sim DA, Keane PA, Patel PJ, Westcott MC, Lee RW, Tufail A, Pavesio CE. Characterization of punctate inner choroidopathy using enhanced depth imaging optical coherence tomography. Ophthalmology. 2014 Sep;121(9):1790-7. doi: 10.1016/j.ophtha.2014.03.011. Epub 2014 May 20. — View Citation


Type Measure Description Time frame Safety issue
Primary Diagnostic criteria of PIC in high or pathological myopic. Pick up the characteristic fundus feature and OCT finding of inflammatory lesion in pathological myopia cases about 7 mounth
Primary Calculate the progression rate of PIC related lesion. By measure the size of patchy atrophy changes during follow-up. about 7 mounth
Primary Development of complication as inflammatory choroidal neovascularization. Pick up the occurrence of inflammatory CNV during follow up period on fundus picture OCT images ,FA , and OCTA about 7 mounth
Secondary Prevalence of PIC in pathological myopia. The number of PIC patients in pathological myopia during this retrospective study of long follow up period about 7 mounth
Secondary Final visual acuity. show the visual acuity of each patients at initial and last visits about 7 mounth
See also
  Status Clinical Trial Phase
Completed NCT03897192 - Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis
Completed NCT03793400 - Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor